

COMPASS news

(<https://compasspathways.com/category/articles/compass-news/>) May 09, 2022

COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults



(/#linkedin)

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient outcomes, has announced that it has funded a study of COMP360 psilocybin in autistic adults. The double-blind, randomised, placebo-controlled study ("PSILAUT") will investigate whether there is a difference in Psychology & Neuroscience (IoPPN) at King's College London. The study is co-sponsored by King's IoPPN and South



(/#twitter)

The study is led by Professor Grainne McAlonan, Professor of Translational Neuroscience at King's IoPPN, and conducted at the University of Cambridge are collaborators and external advisors.



(/#facebook)

Professor Grainne McAlonan, IoPPN, said: "I am delighted that COMPASS Pathways is supporting our investigations into the potential of COMP360 psilocybin in autistic adults."

Professor McAlonan has previously led other studies in autism at King's IoPPN. Klara, a participant on an earlier study becomes more accepting of people who are neurodiverse."



(/#email)

Dr Guy Goodwin, Chief Medical Officer, COMPASS Pathways, said: "We are pleased to fund this innovative research, which has the potential to improve the lives of autistic adults."

For information about taking part in the study, contact Tobias Whelan at mrs@kcl.ac.uk (<mailto:mrs@kcl.ac.uk>).

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the FDA. The study was conducted, and our topline data showed a statistically significant ($p < 0.001$) and clinically relevant improvement in depression symptoms in patients treated with COMP360 compared to placebo in a Phase 3 study conducted in New York and San Francisco in the US. Our vision is a world of mental wellbeing. www.compasspathways.com (<http://www.compasspathways.com>)

Availability of other information about COMPASS Pathways

Investors and others should note that we communicate with our investors and the public using our website (www.coi.com) and other channels. Information disclosed through these channels and websites could be deemed to be material information. As a result, we encourage investors, the media and others to use these channels, or any other website that may be accessed from our website or these channels, shall not be deemed

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include COMPASS's expectations regarding its plans to bring its product candidates to patients, including COMP360, and COMPASS's expectations regarding the timing of regulatory review and approval of COMP360, which could cause actual results, levels of activity, performance or achievements to differ materially from those stated or implied by such forward-looking statements.

These risks, uncertainties, and other factors include, among others: preclinical research and clinical development is I (SEC) on 24 February 2022 and in subsequent filings made by COMPASS with the SEC, which are available on the SE current expectations and speak only as of the date hereof.

About King's College London and the Institute of Psychiatry, Psychology & Neuroscience

King's College London (<https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.kcl.ac.uk%2F&data=04%7C01%7Cserena.rianjongdee%40kcl.ac.uk%7C112675f70fa64>) is one of the top 35 UK universities in the world **and one of the top 10 in Europe** (QS World University Rankings, 2021). King's College London (IoPPN) at King's is the premier centre for mental health and related neurosciences research in Europe. It produces research to prevent and treat mental illness and other conditions that affect the brain. www.kcl.ac.uk/ioppn (<https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.kcl.ac.uk%2Fioppn%2F&data=04%7C01%7Cserena.rianjongdee%40kcl.ac.uk%7C112675f70fa64>)

About South London and Maudsley NHS Foundation Trust

South London and Maudsley NHS Foundation Trust is a large and complex multi-site provider of mental health services and community services across Lambeth, Lewisham, Southwark and Croydon. We also provide substance misuse services.

Enquiries

Media: Amy Lawrence, amy@compasspathways.com, +44 7813 777 919

Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

[Home](#) [/https://compasspathways.com/](https://compasspathways.com) - COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

Useful links

[Contact us](#)
[\(https://compasspathways.com/contact-us/\)](https://compasspathways.com/contact-us/)

[Our results](#)
[\(https://compasspathways.com/our-work/comp360-psilocybin-therapy-in-trd/\)](https://compasspathways.com/our-work/comp360-psilocybin-therapy-in-trd/)

[About psilocybin therapy](#)
[\(https://compasspathways.com/our-work/about-psilocybin-therapy/\)](https://compasspathways.com/our-work/about-psilocybin-therapy/)

[About us](#)
[\(https://compasspathways.com/about-us/\)](https://compasspathways.com/about-us/)

[Join us](#)
[\(https://compasspathways.com/join-us/\)](https://compasspathways.com/join-us/)

[News & views](#)
[\(https://compasspathways.com/news-views/\)](https://compasspathways.com/news-views/)

[Annual Review 2021](#)
[\(https://compasspathways.com/annual-review-2021/\)](https://compasspathways.com/annual-review-2021/)

Follow us

Sign up to receive the latest COMPASS news.

[Subscribe](#)
[/https://compasspathways.com/contact](https://compasspathways.com/contact)

This website is powered by renewable energy

